Aarti Drugs Limited has released its audited financial results for the quarter and financial year ended March 31, 2026. The company reported strong performance, with a consolidated annual revenue of ₹2,56,531 lakhs and an annual profit of ₹19,494 lakhs. Additionally, the Board approved the re-appointment of key auditors and finalized the re-constitution of the Risk Management Committee, marking significant governance updates for the upcoming fiscal year.
Financial Performance Highlights
For the financial year ended March 31, 2026, Aarti Drugs Limited demonstrated robust operational growth. On a consolidated basis, the company achieved total annual revenue of ₹2,56,531 lakhs, compared to ₹2,38,703 lakhs in the previous year. The consolidated net profit attributable to the company for the fiscal year stood at ₹19,492 lakhs, reflecting a steady performance in the pharmaceutical sector.
During the final quarter of the fiscal year (Q4: Jan-Mar 2026), the company generated consolidated revenue of ₹72,030 lakhs and a profit of ₹5,526 lakhs, underscoring consistent demand for its core bulk drug and chemical products.
Strategic Governance and Board Decisions
In the board meeting held on May 15, 2026, the company took several strategic steps to strengthen its corporate governance and compliance framework:
- Cost Audit: The Board re-appointed M/s GMVP & Associates LLP as the Cost Auditor for the financial year ending March 31, 2027.
- Internal Audit: M/s Raman S. Shah & Co. has been re-appointed as the Internal Auditor for a three-year term, effective April 1, 2026.
- Risk Management: The Risk Management Committee was re-constituted to include Shri Narendra J. Salvi, a Non-Executive, Non-Independent Director, further diversifying the oversight capabilities of the committee.
Operational Outlook
The company maintains its commitment to the pharmaceutical industry, operating as a single-segment business. With the appointment of experienced auditing firms and a streamlined committee structure, Aarti Drugs is well-positioned to navigate the upcoming fiscal year 2026-27 with a focus on sustained operational efficiency and financial transparency.
Source: BSE
